GlassScriptPhysician profile
Alison O Moon
NPI 1740349950
$3,205.71
in general payments reported to CMS, 2019-2025
26 companies · $553 in 2025
The $553 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $324 · 2020: $106 · 2021: $447 · 2022: $651 · 2023: $534 · 2024: $592 · 2025: $553.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,594 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,593.56 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $446.83 | 2021-2022 | |
| Arcutis Biotherapeutics, INC. | $377.92 | 2024-2025 | Zoryve |
| Abbvie INC. | $357.74 | 2019-2023 | |
| Pfizer INC. | $303.99 | 2019-2025 | |
| Janssen Biotech, INC. | $234.87 | 2019-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $203.08 | 2019-2025 | Blu-U, Odomzo, Ilumya |
| E.R. Squibb & Sons, L.L.C. | $174.76 | 2022-2024 | Sotyktu |
| Genzyme Corporation | $167.25 | 2019-2022 | |
| Ucb, INC. | $165.04 | 2023-2025 | Bimzelx |
| Amgen INC. | $162.56 | 2020-2025 | Otezla, Otezla |
| Incyte Corporation | $144.34 | 2021-2022 | |
| Almirall LLC | $70.44 | 2023-2025 | Klisyri, Seysara |
| Celgene Corporation | $68.55 | 2019 | |
| Lilly USA, LLC | $64.79 | 2019-2023 | Olumiant, Taltz |
| Galderma Laboratories, L.P. | $51.15 | 2019-2025 | Aklief |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.79 | 2024 | Spevigo |
| Leo Pharma INC. | $26.98 | 2024 | Adbry |
| Novartis Pharmaceuticals Corporation | $24.70 | 2025 | |
| Verrica Pharmaceuticals INC. | $19.15 | 2023 | Ycanth |
| Journey Medical Corporation | $17.85 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $17.41 | 2021 | |
| Aclaris Therapeutics, INC. | $17.19 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $16.85 | 2019 | |
| Vyne Pharmaceuticals INC. | $15.16 | 2021 | |
| Paratek Pharmaceuticals, INC. | $14.30 | 2023 | Nuzyra |
| Epi Health, LLC | $14.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alison Moon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.